Physician profile
Peter Chansky
NPI 1356846588
$42,581.03
in general payments reported to CMS, 2019-2025
29 companies · $27K in 2025
The $27K reported for 2025 was more than what 95% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,316 · 2023: $6,464 · 2024: $8,262 · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $23K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $8,664 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,899 · Consulting Fee: $3,006 · Travel and Lodging: $1,423 · Education: $288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $22,983.96 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $8,664.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,899.00 |
| Consulting Fee | $3,006.00 |
| Travel and Lodging | $1,423.33 |
| Education | $288.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $12,964.15 | 2022-2025 | Winlevi, Absorica Ld, Ilumya |
| Abbvie INC. | $6,004.93 | 2022-2025 | Skyrizi, Rinvoq |
| Genzyme Corporation | $5,874.44 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $3,993.93 | 2022-2025 | Dupixent, Libtayo |
| Lilly USA, LLC | $1,856.07 | 2022-2025 | Taltz, Olumiant, Ebglyss |
| Leo Pharma INC. | $1,653.01 | 2022-2025 | Adbry, Anzupgo, Spevigo |
| Arcutis Biotherapeutics, INC. | $1,604.82 | 2023-2025 | Zoryve |
| Galderma Laboratories, L.P. | $1,266.47 | 2022-2025 | Nemluvio, Dysport |
| Incyte Corporation | $1,011.08 | 2022-2025 | Opzelura |
| Ucb, INC. | $983.55 | 2022-2025 | Bimzelx |
| Janssen Biotech, INC. | $910.31 | 2023-2025 | Tremfya, Simponi, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $729.46 | 2022-2025 | Sotyktu |
| Amgen INC. | $722.51 | 2023-2025 | Otezla |
| Novartis Pharmaceuticals Corporation | $620.29 | 2022-2025 | |
| Pfizer INC. | $469.87 | 2023-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $426.61 | 2022-2024 | Vtama |
| Organon LLC | $376.67 | 2025 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $273.06 | 2022-2025 | Spevigo, Cyltezo |
| Eli Lilly and Company | $209.21 | 2024-2025 | Ebglyss |
| Strata Skin Sciences, INC. | $190.67 | 2022-2025 | Xtrac |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $188.15 | 2023-2025 | Jublia, Cabtreo, Arazlo |
| Journey Medical Corporation | $59.82 | 2023-2025 | |
| Merz North America, INC. | $33.99 | 2023 | |
| Genentech USA, INC. | $31.14 | 2025 | Xolair |
| Biofrontera INC. | $29.08 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
| Organogenesis INC. | $25.73 | 2023 | Puraply |
| Verrica Pharmaceuticals INC. | $24.73 | 2025 | Ycanth |
| Cipher Pharmaceuticals US LLC | $24.58 | 2025 | Spinosad, Natroba |
| Almirall LLC | $22.70 | 2025 | Klisyri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Chansky listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.